{"id":"https://openalex.org/W4361886407","doi":"https://doi.org/10.1158/1078-0432.22465484","title":"Supplementary Tables and Figures from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer","display_name":"Supplementary Tables and Figures from Phase I Study of Single-Agent Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Patients with Advanced Cancer","publication_year":2023,"publication_date":"2023-03-31","ids":{"openalex":"https://openalex.org/W4361886407","doi":"https://doi.org/10.1158/1078-0432.22465484"},"language":"en","primary_location":{"id":"doi:10.1158/1078-0432.22465484","doi":"https://doi.org/10.1158/1078-0432.22465484","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22465484","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"volume":null,"type":"supplementary-materials","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"http://dx.doi.org/10.1158/1078-0432.22465484","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062202820","display_name":"Neil Howard Segal","orcid":"https://orcid.org/0000-0002-3047-2303","observed_orcids":["https://orcid.org/0000-0002-3047-2303"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Neil H. Segal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5045096676","display_name":"Aiwu Ruth He","orcid":"https://orcid.org/0000-0002-2104-0816","observed_orcids":["https://orcid.org/0000-0002-2104-0816"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aiwu R. He","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001115937","display_name":"Toshihiko Doi","orcid":"https://orcid.org/0000-0003-2042-6829","observed_orcids":["https://orcid.org/0000-0003-2042-6829"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Toshihiko Doi","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083342021","display_name":"Ronald Levy","orcid":"https://orcid.org/0000-0003-2061-0650","observed_orcids":["https://orcid.org/0000-0003-2061-0650"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ronald Levy","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034786338","display_name":"Shailender Bhatia","orcid":"https://orcid.org/0000-0002-3816-2238","observed_orcids":["https://orcid.org/0000-0002-3816-2238"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Shailender Bhatia","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5021453899","display_name":"Michael Jon Pishvaian","orcid":"https://orcid.org/0000-0002-1165-9041","observed_orcids":["https://orcid.org/0000-0002-1165-9041"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Michael J. Pishvaian","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5026606309","display_name":"Rossano Cesari","orcid":"https://orcid.org/0009-0008-3757-3220","observed_orcids":["https://orcid.org/0009-0008-3757-3220"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Rossano Cesari","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100383091","display_name":"Ying Chen","orcid":"https://orcid.org/0000-0002-8884-3138","observed_orcids":["https://orcid.org/0000-0002-8884-3138"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ying Chen","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072398101","display_name":"Craig B. Davis","orcid":"https://orcid.org/0000-0002-1703-451X","observed_orcids":["https://orcid.org/0000-0002-1703-451X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Craig B. Davis","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100705731","display_name":"Bo Huang","orcid":"https://orcid.org/0000-0002-5063-3522","observed_orcids":["https://orcid.org/0000-0002-5063-3522"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Bo Huang","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015049606","display_name":"Aron D. Thall","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Aron D. Thall","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5004025497","display_name":"Ajay K. Gopal","orcid":"https://orcid.org/0000-0003-3023-6834","observed_orcids":["https://orcid.org/0000-0003-3023-6834"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Ajay K. Gopal","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10158","display_name":"Cancer Immunotherapy and Biomarkers","score":0.9682999849319458,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.020099999383091927,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10031","display_name":"T-cell and B-cell Immunology","score":0.0034000000450760126,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/utomilumab","display_name":"utomilumab","score":0.9990000128746033},{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.5920000076293945},{"id":"https://openalex.org/keywords/advanced-cancer","display_name":"advanced cancer","score":0.8479999899864197},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.6930000185966492},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8870000243186951},{"id":"https://openalex.org/keywords/anti-drug-antibodies","display_name":"anti-drug antibodies","score":0.7179999947547913},{"id":"https://openalex.org/keywords/lymphocyte-subsets","display_name":"lymphocyte subsets","score":0.8389999866485596},{"id":"https://openalex.org/keywords/treatment-discontinuation","display_name":"treatment discontinuation","score":0.7099999785423279},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.699999988079071}],"concepts":[{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.7349492311477661},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.4906822443008423},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.41858574748039246},{"id":"https://openalex.org/C2778938600","wikidata":"https://www.wikidata.org/wiki/Q389934","display_name":"Agonist","level":3,"score":0.41692090034484863},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.38643351197242737},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.38234975934028625},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.371131956577301},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08243095874786377}],"mesh":[],"locations_count":3,"locations":[{"id":"doi:10.1158/1078-0432.22465484","doi":"https://doi.org/10.1158/1078-0432.22465484","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22465484","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"doi:10.1158/1078-0432.22465484.v1","doi":"https://doi.org/10.1158/1078-0432.22465484.v1","is_oa":true,"landing_page_url":"https://doi.org/10.1158/1078-0432.22465484.v1","pdf_url":"https://aacr.figshare.com/ndownloader/files/39916817","source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},{"id":"pmh:oai:figshare.com:article/22465484","doi":null,"is_oa":true,"landing_page_url":"https://figshare.com/articles/journal_contribution/Supplementary_Tables_and_Figures_from_Phase_I_Study_of_Single-Agent_Utomilumab_PF-05082566_a_4-1BB_CD137_Agonist_in_Patients_with_Advanced_Cancer/22465484","pdf_url":null,"source":{"id":"https://openalex.org/S4377196282","display_name":"Figshare","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I4210132348","host_organization_name":"Figshare (United Kingdom)","host_organization_lineage":["https://openalex.org/I4210132348"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"","raw_type":"Text"}],"best_oa_location":{"id":"doi:10.1158/1078-0432.22465484","doi":"https://doi.org/10.1158/1078-0432.22465484","is_oa":true,"landing_page_url":"http://dx.doi.org/10.1158/1078-0432.22465484","pdf_url":null,"source":null,"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"American Association for Cancer Research","raw_type":"posted-content"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W4361886407.pdf","grobid_xml":"https://content.openalex.org/works/W4361886407.grobid-xml"},"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2792883957","https://openalex.org/W4361946036","https://openalex.org/W4361889200","https://openalex.org/W4361868812","https://openalex.org/W6920681534","https://openalex.org/W6957805525","https://openalex.org/W2622137068","https://openalex.org/W2711497375","https://openalex.org/W4361957768","https://openalex.org/W4361946660"],"abstract_inverted_index":{"Supplementary":[0,7,17,27,32,50],"Table":[1,8,18],"S1.":[2,29],"Reason":[3],"for":[4,22],"treatment":[5,65],"discontinuation":[6],"S2.":[9,34],"Select":[10],"laboratory":[11],"abnormalities":[12],"by":[13,56],"maximum":[14],"CTCAE":[15],"grade":[16],"S3.":[19,52],"Pharmacokinetic":[20],"parameters":[21],"single-agent":[23,39],"utomilumab":[24,40],"(cycle":[25,46],"1)":[26],"Figure":[28,33,51],"Patient":[30],"disposition.":[31],"Dose":[35],"normalized":[36],"Cmax":[37],"of":[38],"in":[41],"ADA-negative":[42],"and":[43],"ADA-positive":[44],"patients":[45],"2,":[47],"day":[48],"1).":[49],"Lymphocyte":[53],"subpopulations":[54],"assessed":[55],"flow":[57],"cytometry":[58],"over":[59],"an":[60],"8-week":[61],"(2-cycle)":[62],"period":[63],"following":[64],"with":[66],"utomilumab.":[67]},"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2023-04-05T00:00:00"}